(616 Kb) May 2026

The search for a "616 KB" article points directly to a significant medical study titled

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials (616 KB)

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. The search for a "616 KB" article points

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression). : Interestingly, the most common reason for stopping

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .